Exploring the role of RB and AR in a phase II randomized multicenter trial of abiraterone acetate with or without cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC)

Authors

• William Kelly

Publication/Presentation Date

5-2016

Volume

34

Issue

15

Published In/Presented At

DOI: 10.1200/JCO.2016.34.15_suppl.TPS5093

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

Department(s)

Administration and Leadership

Document Type

Article